Imidazopyrimidines, potent inhibitors of p38 MAP kinase

被引：267

作者：

Rupert, KC ^{[1
]}

Henry, JR ^{[1
]}

Dodd, JH ^{[1
]}

Wadsworth, SA ^{[1
]}

Cavender, DE ^{[1
]}

Olini, GC ^{[1
]}

Fahmy, B ^{[1
]}

Siekierka, JJ ^{[1
]}

机构：

[1] Johnson & Johnson Pharmaceut Res & Dev, LLC, Drug Discovery, Raritan, NJ 08869 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 03期

关键词：

D O I：

10.1016/S0960-894X(02)01020-X

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-alpha and IL-1beta. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-alpha in vivo. (C) 2002 Elsevier Science Ltd. All rights reserved.

引用

页码：347 / 350

页数：4

共 50 条

[41] Effects of p38 MAP Kinase Inhibitors on the Differentiation and Maturation of Erythroid Progenitors
Dalmas, Deidre A.
Tierney, Lauren A.
Zhang, Cindy
Narayanan, Padma K.
Boyce, Rogely W.
Schwartz, Lester W.
Frazier, Kendall S.
Scicchitano, Marshall S.
TOXICOLOGIC PATHOLOGY, 2008, 36 (07) : 958 - 971
[42] Discovery and design of novel benzimidazolone as inhibitors of p38 MAP kinase.
Hammach, A
Ralph, M
Corbo, F
Barbosa, A
Liu, PR
Soleymanzadeh, F
Goldberg, D
Sarko, C
Mckibben, B
Moss, N
Hao, MH
White, A
Qian, K
Pargellis, C
Kroe, R
Wildeson, J
Nelson, R
Fadra, T
Capolino, A
Kashem, M
Patnaude, L
Madwed, J
Torcellini, C
Kaplita, P
Farrel, T
Hu, HB
Yazdania, M
Kavanaugh, K
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U947 - U947
[43] 4-azaindoles: Novel inhibitors of p38 MAP kinase.
Trejo, A
Arzeno, H
Browner, M
Cheng, SA
Corner, DD
Dalrymple, S
Freire-Moar, J
Lim, J
Mcintosh, J
Miller, J
Myers, PL
Saunders, J
Sjogren, EB
Spellmyer, D
Warren, SD
Whiteley, PE
Zeng, L
Goldstein, DM
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U59 - U59
[44] Binding modes of known classes of p38 MAP kinase inhibitors.
Moss, N
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U437 - U437
[45] Identification of p38α MAP kinase inhibitors by pharmacophore based virtual screening
Gangwal, Rahul P.
Das, Nihar R.
Thanki, Kaushik
Damre, Mangesh V.
Dhoke, Gaurao V.
Sharma, Shyam S.
Jain, Sanyog
Sangamwar, Abhay T.
JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2014, 49 : 18 - 24
[46] Inhibitors of p38 MAP kinase increase the survival of transplanted dopamine neurons
Zawada, WM
Meintzer, MK
Rao, P
Marotti, J
Wang, XM
Esplen, JE
Clarkson, ED
Freed, CR
Heidenreich, KA
BRAIN RESEARCH, 2001, 891 (1-2) : 185 - 196
[47] Quantitative structure activity relationship study of p38α MAP kinase inhibitors
Pourbasheer, Eslam
Ahmadpour, Sajjad
Zare-Dorabei, Rohollah
Nekoei, Mehdi
ARABIAN JOURNAL OF CHEMISTRY, 2017, 10 (01) : 33 - 40
[48] SAR of benzoylpyridines and benzophenones as p38α MAP kinase inhibitors with oral activity
Revesz, L
Blum, E
Di Padova, FE
Buhl, T
Feifel, R
Gram, H
Hiestand, P
Manning, U
Rucklin, G
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, 14 (13) : 3601 - 3605
[49] Design, synthesis, and SAR of a novel series of p38α MAP kinase inhibitors
Martin, Barrie P.
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
[50] Design of potent and selective 2-aminobenzimidazole-based p38α MAP kinase inhibitors with excellent in vivo efficacy
de Dios, A
Shih, C
de Uralde, BL
Sánchez, C
Del Prado, M
Cabrejas, LMM
Pleite, S
Blanco-Urgoiti, J
Lorite, MJ
Nevill, CR
Bonjouklian, R
York, J
Vieth, M
Wang, Y
Magnus, N
Campbell, RM
Anderson, BD
McCann, DJ
Giera, DD
Lee, PA
Schultz, RM
Li, LC
Johnson, LM
Wolos, JA
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (07) : 2270 - 2273

← 1 2 3 4 5 →